LeonaBio Inc. (LONA) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 23% of 52W Range • RSI-14 at 43.7 (NEUTRAL RANGE)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While LONA currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.05) and Max Pain ($5.16) forces dealer call-delta covering toward $14.92.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
LeonaBio Inc. (LONA) slipped -1.01% to $4.91, trading at 23% of its 52-week range ($2.21 – $14.21). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 16.1% to $0.92 during Thursday's after-market session. The company's market cap stands at $2.2 million. CareDx (NASDAQ:CDNA) stock rose 15.0% to $82.25.
Gainers Profusa (NASDAQ:PFSA) shares moved upwards by 35.4% to $1.15 during Thursday's regular session. Karyopharm Therapeutics (NASDAQ:KPTI) shares increased by 29.12% to $0.55. The company's market cap
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on LONA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for LONA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, LeonaBio Inc. (LONA) ranks #587 by composite RQD confidence (42/100, grade D-) and #761 by equity capitalization ($46.3M). Within this direct 5-issuer industry benchmark cohort, LONA leads on earnings valuation at N/A trailing P/E, while LONA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. TIL currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with LONA at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LONA
ACTIVE
LeonaBio Inc. | D- | 42/100 | — | — | -35.0% | -1.01% | $46.3M | Benchmark Subject |
| TIL Instil Bio Inc. | D | 51/100 | — | — | -35.0% | +0.52% | $46.3M | /til-vs-lona → |
| IMA ImageneBio Inc. | E | 24/100 | — | — | -35.0% | -3.57% | $46.0M | /ima-vs-lona → |
| CRBU Caribou Biosciences Inc. | D- | 43/100 | — | — | -35.0% | -9.07% | $47.7M | /crbu-vs-lona → |
| INMB INmune Bio Inc. | D | 45/100 | — | — | -35.0% | +4.58% | $44.4M | /inmb-vs-lona → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), LeonaBio Inc. (LONA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$106.0M, operating cash flow of -$45.7M, and free cash flow of -$45.7M (+53.0% YoY). On the balance sheet, LONA closed FY2025 with $92.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$106.0M | -$45.7M | -$45.7M | $92.2M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$97.0M | -$97.2M | -$97.2M | $58.8M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$117.7M | -$100.8M | -$100.8M | — | — |
As of 2026-11-01, LeonaBio Inc. (NASDAQ: LONA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $4.91 (-1.01% 1D, market cap $46.3M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, LONA ranks #587 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), LONA carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, TIL (Instil Bio Inc.) holds a D grade (51/100 RQD, P/E N/A, ROIC -35.0%, cap $46.3M) and IMA (ImageneBio Inc.) posts a E grade (24/100 RQD, P/E N/A, ROIC -35.0%, cap $46.0M). Among the 5-stock peer group, LONA leads on earnings multiple (N/A) while LONA leads on capital efficiency (-35.0% ROIC).
Per LONA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001620463), LeonaBio Inc. generated $0 in revenue, -$106.0M in net income, and -$45.7M in free cash flow against $92.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
LONA last traded at $4.91 (-1.01% on volume of 162,059 shares), positioning the stock -18.84% below its 50-day simple moving average ($6.05) and -34.62% below its 200-day simple moving average ($7.51). Across its 52-week range of $2.21 to $14.21, LONA sits at the 22.5% percentile with a 14-day RSI of 43.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.30 to $5.52).
Why LONA Stock slipped -1.01% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.